Lutetium-177 Chloride Radiochemical

Used in targeted radionuclide therapy for neuroendocrine tumors and prostate cancer.


Half Life:

Lutetium-177 (Lu-177) is a radioisotope used in targeted radionuclide therapy to treat certain neuroendocrine tumors and prostate cancer. Lu-177 can be combined with tumor-targeting vectors that guide the isotope to diseased cells within the body and attaches to them. 

As the Lu-177 undergoes radioactive decay, it delivers a large dose of beta particles that can destroy the diseased cells. Lu-177-based radiotherapies have achieved success in a variety of types of cancer.

Sales Inquiries:

Call 1.800.267.6211 (North America) or 1.613.963.2621 (International).

Data Sheet

This Website Uses Cookies.

We use cookies to give you the best user experience. No personal information is collected in this process.